4/16
11:15 am
atos
Atossa Therapeutics, Inc. (NASDAQ: ATOS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $4.00 price target on the stock.
Medium
Report
Atossa Therapeutics, Inc. (NASDAQ: ATOS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $4.00 price target on the stock.
4/15
08:30 am
atos
Atossa Therapeutics and Quantum Leap Healthcare Announce I-SPY 2 Clinical Trial to Evaluate (Z)-Endoxifen in Combination with Abemaciclib (VERZENIO®) in Women with ER+/HER2- Breast Cancer
Medium
Report
Atossa Therapeutics and Quantum Leap Healthcare Announce I-SPY 2 Clinical Trial to Evaluate (Z)-Endoxifen in Combination with Abemaciclib (VERZENIO®) in Women with ER+/HER2- Breast Cancer
4/11
11:41 am
atos
Atossa (ATOS) Reports Positive Results From EVANGELINE Study [Yahoo! Finance]
Low
Report
Atossa (ATOS) Reports Positive Results From EVANGELINE Study [Yahoo! Finance]
4/11
08:37 am
atos
Atossa to Participate in Noble Capital Markets Emerging Growth Healthcare Conference [Yahoo! Finance]
Low
Report
Atossa to Participate in Noble Capital Markets Emerging Growth Healthcare Conference [Yahoo! Finance]
4/11
08:30 am
atos
Atossa to Participate in Noble Capital Markets Emerging Growth Healthcare Conference
Low
Report
Atossa to Participate in Noble Capital Markets Emerging Growth Healthcare Conference
4/9
12:12 pm
atos
Atossa Therapeutics Presents Data from 40mg Cohort of Phase 2 EVANGELINE Clinical Trial Showing 100% Disease Control Rate After 24-Weeks of Treatment with (Z)-Endoxifen [Yahoo! Finance]
Low
Report
Atossa Therapeutics Presents Data from 40mg Cohort of Phase 2 EVANGELINE Clinical Trial Showing 100% Disease Control Rate After 24-Weeks of Treatment with (Z)-Endoxifen [Yahoo! Finance]
4/9
11:59 am
atos
Atossa Therapeutics Presents Data from 40mg Cohort of Phase 2 EVANGELINE Clinical Trial Showing 100% Disease Control Rate After 24-Weeks of Treatment with (Z)-Endoxifen
Low
Report
Atossa Therapeutics Presents Data from 40mg Cohort of Phase 2 EVANGELINE Clinical Trial Showing 100% Disease Control Rate After 24-Weeks of Treatment with (Z)-Endoxifen
4/2
09:01 am
atos
Atossa Therapeutics, Inc. (NASDAQ: ATOS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $4.00 price target on the stock.
High
Report
Atossa Therapeutics, Inc. (NASDAQ: ATOS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $4.00 price target on the stock.
4/1
04:09 pm
atos
Atossa Therapeutics Announces Year-End 2023 Financial Results and Provides Corporate Update [Yahoo! Finance]
Medium
Report
Atossa Therapeutics Announces Year-End 2023 Financial Results and Provides Corporate Update [Yahoo! Finance]
4/1
04:00 pm
atos
Atossa Therapeutics Announces Year-End 2023 Financial Results and Provides Corporate Update
Medium
Report
Atossa Therapeutics Announces Year-End 2023 Financial Results and Provides Corporate Update
3/26
09:31 am
atos
Thinking about buying stock in Cardiff Oncology, BIOLASE, Akebia Therapeutics, Astera Labs, or Atossa Therapeutics?
Medium
Report
Thinking about buying stock in Cardiff Oncology, BIOLASE, Akebia Therapeutics, Astera Labs, or Atossa Therapeutics?
3/20
09:31 am
atos
Thinking about buying stock in Pixelworks, Backblaze, Praxis Precision Medicines, Scworx, or Atossa Therapeutics?
Low
Report
Thinking about buying stock in Pixelworks, Backblaze, Praxis Precision Medicines, Scworx, or Atossa Therapeutics?
3/19
08:45 am
atos
Atossa Therapeutics Provides Five-Year (Z)-Endoxifen Treatment Update on FDA-Approved "Expanded Access" Program for a U.S. Breast Cancer Patient [Yahoo! Finance]
High
Report
Atossa Therapeutics Provides Five-Year (Z)-Endoxifen Treatment Update on FDA-Approved "Expanded Access" Program for a U.S. Breast Cancer Patient [Yahoo! Finance]
3/19
08:30 am
atos
Atossa Therapeutics Provides Five-Year (Z)-Endoxifen Treatment Update on FDA-Approved "Expanded Access" Program for a U.S. Breast Cancer Patient
High
Report
Atossa Therapeutics Provides Five-Year (Z)-Endoxifen Treatment Update on FDA-Approved "Expanded Access" Program for a U.S. Breast Cancer Patient
3/18
11:06 pm
atos
Atossa Therapeutics, Inc. (NASDAQ: ATOS) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
High
Report
Atossa Therapeutics, Inc. (NASDAQ: ATOS) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
3/18
08:57 am
atos
Atossa Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Listing Requirements [Yahoo! Finance]
Low
Report
Atossa Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Listing Requirements [Yahoo! Finance]
3/18
08:30 am
atos
Atossa Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Listing Requirements
Low
Report
Atossa Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Listing Requirements
3/12
08:52 am
atos
Atossa Therapeutics Appoints Breast Cancer Specialist Tessa Cigler, M.D., M.P.H. to its Board of Directors [Yahoo! Finance]
Medium
Report
Atossa Therapeutics Appoints Breast Cancer Specialist Tessa Cigler, M.D., M.P.H. to its Board of Directors [Yahoo! Finance]
3/12
08:30 am
atos
Atossa Therapeutics Appoints Breast Cancer Specialist Tessa Cigler, M.D., M.P.H. to its Board of Directors
Medium
Report
Atossa Therapeutics Appoints Breast Cancer Specialist Tessa Cigler, M.D., M.P.H. to its Board of Directors
3/6
08:51 am
atos
Data from Atossa's Phase 2 EVANGELINE Clinical Trial to be Presented at American Association for Cancer Research (AACR) Annual Meeting [Yahoo! Finance]
High
Report
Data from Atossa's Phase 2 EVANGELINE Clinical Trial to be Presented at American Association for Cancer Research (AACR) Annual Meeting [Yahoo! Finance]
3/6
08:30 am
atos
Data from Atossa’s Phase 2 EVANGELINE Clinical Trial to be Presented at American Association for Cancer Research (AACR) Annual Meeting
High
Report
Data from Atossa’s Phase 2 EVANGELINE Clinical Trial to be Presented at American Association for Cancer Research (AACR) Annual Meeting
3/3
09:36 am
atos
We Think Atossa Therapeutics (NASDAQ:ATOS) Can Afford To Drive Business Growth [Yahoo! Finance]
Medium
Report
We Think Atossa Therapeutics (NASDAQ:ATOS) Can Afford To Drive Business Growth [Yahoo! Finance]
2/22
08:35 am
atos
Atossa Therapeutics Announces First Patient Dosing of (Z)-Endoxifen in the Ongoing RECAST DCIS Study [Yahoo! Finance]
Low
Report
Atossa Therapeutics Announces First Patient Dosing of (Z)-Endoxifen in the Ongoing RECAST DCIS Study [Yahoo! Finance]
2/22
08:30 am
atos
Atossa Therapeutics Announces First Patient Dosing of (Z)-Endoxifen in the Ongoing RECAST DCIS Study
Low
Report
Atossa Therapeutics Announces First Patient Dosing of (Z)-Endoxifen in the Ongoing RECAST DCIS Study
2/12
08:09 am
atos
Atossa Therapeutics, Inc. (NASDAQ: ATOS) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $4.00 price target on the stock.
Medium
Report
Atossa Therapeutics, Inc. (NASDAQ: ATOS) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $4.00 price target on the stock.